Fig. 3
From: Exploiting RIG-I-like receptor pathway for cancer immunotherapy
Therapeutic targeting RLRs in cancer. a RLRs can be activated by synthetic RNA, dsDNA or bifunctional 5′-ppp siRNA. b Oncolytic virus infection may induce RLRs signaling and sensitize tumors to immune checkpoint blockade (ICB). c Viral mimicry is a strategy to activate RLRs-mediated antitumor immunity. d Radio-chemotherapy-induced DNA damage and mitochondrial RNA (mtRNA) release trigger RLRs signaling and sensitize tumors to ICB